Rye Brook Capital’s Astera Labs ALAB Stock Holding History

Rye Brook Capital’s Portfolio ALAB Stock Details ALAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,285	Closed	-$579K	–	44
2026 Q1	$579K	Sell	5,285 -3,915	-43%	-$558K	0.53%	21
2025 Q4	$1.53M	Hold	9,200	–	–	1.43%	15
2025 Q3	$1.8M	Buy	9,200 +100	+1%	+$16.4K	0.94%	17
2025 Q2	$823K	Buy	+9,100	New	+$719K	0.86%	17

Other funds holding ALAB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CIA

Capital Impact Advisors Boston, Massachusetts $1.78B AUM 56.11% 1-Year Est. Return

VAM

Valliance Asset Management Central, Hong Kong $864M AUM 906.77% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

ACI

Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return

Rye Brook Capital's ALAB Position: Q2 2026 in Review

Rye Brook Capital sold out of Astera Labs (ALAB) in Q2 2026, closing a stake of 5,285 shares — an estimated $579K sold.

Rye Brook Capital first reported a position in ALAB in Q2 2025 and held it in 4 quarters. The position peaked at $1.8M in Q3 2025. 544 funds tracked by Wall St. Rank hold ALAB as of Q2 2026.

Rye Brook Capital reported no remaining Astera Labs position as of Q2 2026 after selling out during the quarter.
Rye Brook Capital sold 5,285 Astera Labs shares in Q2 2026, an estimated $579K.
Rye Brook Capital first reported a position in Astera Labs in Q2 2025 and held it in 4 quarters.
Rye Brook Capital's Astera Labs position peaked at $1.8M in Q3 2025.
544 funds tracked by Wall St. Rank held Astera Labs as of Q2 2026.

Based on Rye Brook Capital's 13F filing for Q2 2026, filed 20 Jul 2026.